Kaeros sees ₹200 crore standalone business and brand doubling

In the current fiscal, Insecticides India Limited said its Kaeros platform is part of a business that may close at about ₹200 crore on a standalone basis, while total brand business may reach about ₹125 crore and management expects brand business to double next fiscal. The call did not disclose Kaeros revenue separately.

What business target has Kaeros set for this fiscal?

Management expects about ₹125 crore of total brand business in the current fiscal, while IIL may close at about ₹200 crore in standalone results. Rajesh Aggarwal presented both as expectations rather than reported results after describing Kaeros as an engine of growth for the company’s products and brand reach.

The ₹200 crore figure applies to IIL’s standalone business, not to a separately disclosed Kaeros revenue line. Management did not provide Kaeros’s current revenue, profit or margin, so the call does not establish what portion of the ₹125 crore brand-business estimate is generated by Kaeros rather than IIL’s other branded operations.

Management said Kaeros could grow at a compound annual growth rate, or CAGR, of no less than 50%, with growth in the next fiscal potentially higher. Aggarwal added that 100% CAGR would not be unexpected next fiscal, but this was a management expectation linked to network expansion and products entering the market, not formal financial guidance.

How broad is Kaeros’s product and distribution footprint?

Kaeros had more than 55 products in the market at the time of the call, and management expected about 60 products to be commercialised during the current fiscal. That expansion is central to the plan because IIL is building the platform as a separate brand route for technologies that may not all fit under one company’s existing product structure.

More than 150 people had joined Kaeros through third-party and main-company roles, according to management. The company also said its network had already appointed about 800,000 distributors in the Northeast and western corners of India, without disclosing a state-level split or the sales contribution of those distributors.

Kaeros had yet to enter southern markets fully, but management said it planned to do so shortly and complete the southern network in the second half, or H2, of the current fiscal. If completed, the rollout would open an all-India market network within the fiscal year, compared with the existing presence in the Northeast and western regions.

The expansion is occurring alongside IIL’s broader product-development effort, which management said covers 30 technologies expected over the next two to three years. Aggarwal said the volume of technologies was a reason for establishing Kaeros, although he also said products may need to be divided between the two businesses rather than assigning all future technologies to the platform.

Why does management expect Kaeros brand business to double next fiscal?

Management expects IIL’s brand business to double next fiscal because Kaeros should have a completed national network and a larger product range by then. The expectation follows the current-fiscal plan to reach about 60 products and finish southern-market coverage in H2, but management did not provide a numerical standalone Kaeros sales target for next fiscal.

The comparison is therefore between an estimated ₹125 crore of current-fiscal total brand business and management’s expectation of twice that brand business next fiscal. The call does not specify whether the doubling refers solely to Kaeros or to all IIL brand business, and it does not disclose the preceding fiscal’s brand-business sales base.

New launches are expected to add to the available portfolio, although management said no major launches were visible for the remainder of the current fiscal apart from one or two possible products. For next fiscal, it identified three to five visible launches, while registrations remained in process for the larger 30-technology pipeline.

Management also referred to a planned herbicide launch with Nissan that would use a new mode of action, meaning a different biological mechanism for controlling weeds. It called the product a major Indian requirement but gave no revenue forecast, launch date or indication that it would necessarily be sold through Kaeros.

What product and mix factors could affect Kaeros’s expansion?

Recent launches including Spinoace and Granuvia received a lukewarm response because of low rainfall, according to management, which expected some recovery in H2 during the rabi crop season. This indicates that Kaeros’s product rollout can depend on seasonal farm conditions even after products have been commercialised.

IIL’s wider branded portfolio also includes premium products, whose contribution has moved from about 50% when the strategy was formed to more than 60% currently. Management’s next target is 70%, and it said the shift toward Maharatna and Focused Maharatna products should improve company margins over time, though it did not quantify an impact on Kaeros specifically.

Management said margin improvement could be about 1 percentage point in some years, lower in others and above 1 percentage point in certain years. That is an outlook rather than a forecast tied to a stated base margin, and it remains dependent on product mix, sales growth and execution across IIL’s broader business.

The development pipeline includes an OAT Agrio joint-venture molecule for which IIL had applied for inclusion in the schedule of the Insecticide Act. Management expected clearance within a few months, followed by a registration application, and said the first product could have a chance to reach the market next fiscal after a delay from the earlier 2027 target.

Conclusion

Kaeros is being positioned as a national growth platform rather than only an additional distribution channel: it has more than 55 products, aims for about 60 this fiscal, and is intended to complete southern-market expansion in H2. Management’s ₹125 crore brand-business estimate and ₹200 crore standalone-business expectation provide near-term scale context, but neither figure discloses Kaeros revenue separately.

The next disclosed milestones are completion of the all-India network during the current fiscal, three to five visible launches next fiscal, and progress on registrations across the 30-technology pipeline. Management’s expectation of doubled brand business next fiscal will also depend on the network rollout, product launches and the timing of regulatory approvals, including the OAT Agrio molecule application.